×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Amgen Statement on Jan 27 2014 FDA Warning Letter

THOUSAND OAKS, Calif. (Feb. 11, 2014)

Amgen's commitment to product quality includes the medicines we make and the needles, syringes and other constituent parts used in their administration. Medicines in conjunction with these device constituent parts are known as "combination products."

We received a warning letter from the U.S. Food and Drug Administration (FDA), dated Jan. 27, 2014, describing issues related to the device constituent parts of our combination products.

Amgen takes these issues very seriously and we have implemented changes to our procedures. We are committed to working with the FDA to take appropriate measures and provide the necessary information to address the concerns raised in the letter.

Read more about our commitment to quality.